Arctigenin derivative A‐1 ameliorates motor dysfunction and pathological manifestations in SOD1 G93A transgenic mice via the AMPK / SIRT1 / PGC ‐1α and AMPK / SIRT1 / IL ‐1β/ NF‐κB pathways
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.14692 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Bocheng Xiong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control a…. Hauptthemen laut MEDLINE: Mice, Transgenic, Sirtuin 1, NF-kappa B, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanming Project of Medicine in Shenzhen, National Natural Science Foundation of China, The Key Basic Research Program of Shenzhen Science and Technology Innovation Commission.
Abstract (Originalsprache)
Aim
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by progressive death of upper and lower motor neurons, leading to generalized muscle atrophy, paralysis, and even death. Mitochondrial damage and neuroinflammation play key roles in the pathogenesis of ALS. In the present study, the efficacy of A‐1, a derivative of arctigenin with AMP‐activated protein kinase (AMPK) and silent information regulator 1 (SIRT1) activation for ALS, was investigated.
Methods
A‐1 at 33.3 mg/kg was administrated in SOD1 G93A transgenic mice orally from the 13th week for a 6‐week treatment period. Motor ability was assessed before terminal anesthesia. Muscle atrophy and fibrosis, motor neurons, astrocytes, and microglia in the spinal cord were evaluated by H&E, Masson, Sirius Red, Nissl, and immunohistochemistry staining. Protein expression was detected with proteomics analysis, Western blotting, and ELISA. Mitochondrial adenosine triphosphate (ATP) and malondialdehyde (MDA) levels were measured using an assay kit.
Results
A‐1 administration in SOD1 G93A mice enhanced mobility, decreased skeletal muscle atrophy and fibrosis, mitigated loss of spinal motor neurons, and reduced glial activation. Additionally, A‐1 treatment improved mitochondrial function, evidenced by elevated ATP levels and increased expression of key mitochondrial‐related proteins. The A‐1 treatment group showed decreased levels of IL‐1β, pIκBα/IκBα, and pNF‐κB/NF‐κB.
Conclusions
A‐1 treatment reduced motor neuron loss, improved gastrocnemius atrophy, and delayed ALS progression through the AMPK/SIRT1/PGC‐1α pathway, which promotes mitochondrial biogenesis. Furthermore, the AMPK/SIRT1/IL‐1β/NF‐κB pathway exerted neuroprotective effects by reducing neuroinflammation. These findings suggest A‐1 as a promising therapeutic approach for ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Modern Toxicology, Shenzhen Medical Key Discipline of Health Toxicology (2020-2024), Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
- Department of Neurology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
- Department of Neurology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
- Medical Laboratory, Shenzhen Prevention and Treatment Center for Occupational Diseases, Shenzhen, China.
- State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.
- Institute of New Drug Research, College of Pharmacy/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research/International Cooperative Laboratory of Traditional Chinese Medicine Mo…
ORCID-Profile: Shupeng Li
Förderung
- Sanming Project of Medicine in Shenzhen
- National Natural Science Foundation of China
- The Key Basic Research Program of Shenzhen Science and Technology Innovation Commission
- Shenzhen Key Medical Discipline Construction Fund
Zitieren
APA
Xiong, B., Yang, C., Yang, X., Luo, S., Li, S., Chen, C., He, K., Nie, L., Li, P., Li, S., Huang, H., Liu, J., Zhang, Z., Xie, Y., Zou, L., & Yang, X. (2024). Arctigenin derivative A‐1 ameliorates motor dysfunction and pathological manifestations in SOD1 G93A transgenic mice via the AMPK / SIRT1 / PGC ‐1α and AMPK / SIRT1 / IL ‐1β/ NF‐κB pathways. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.14692
Vancouver
Xiong B, Yang C, Yang X, Luo S, Li S, Chen C, et al. Arctigenin derivative A‐1 ameliorates motor dysfunction and pathological manifestations in SOD1 G93A transgenic mice via the AMPK / SIRT1 / PGC ‐1α and AMPK / SIRT1 / IL ‐1β/ NF‐κB pathways. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.14692
BibTeX
@article{Xiong2024,
author = {Xiong, Bocheng and Yang, Chao and Yang, Xiao and Luo, Song and Li, Shangming and Chen, Chongyang and He, Kaiwu and Nie, Lulin and Li, Peimao and Li, Shupeng and Huang, Haiyan and Liu, Jianjun and Zhang, Zaijun and Xie, Yongmei and Zou, Liangyu and Yang, Xifei},
title = {Arctigenin derivative A‐1 ameliorates motor dysfunction and pathological manifestations in SOD1 G93A transgenic mice via the AMPK / SIRT1 / PGC ‐1α and AMPK / SIRT1 / IL ‐1β/ NF‐κB pathways},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.14692}
}
EUVIMED